Center for Scientific Review; Notice of Closed Meetings, 71080-71081 [2020-24672]
Download as PDF
<![CDATA[
71080
Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices
NIH ref No.
Patent No. or
application No.
Issue date
Filing date
E–140–2014–0–EP–06 ..........
E–140–2014–0–IN–07 ...........
E–140–2014–0–JP–08 ...........
E–140–2014–0–US–09 ..........
E–140–2014–0–HK–10 ..........
E–140–2014–0–AU–11 ..........
15728668.3 ...................
201637038171 ..............
2017–511558 ................
10,329,259 ....................
17105705.6 ...................
2019227889 ..................
...............................................
...............................................
TBD (application allowed) ....
June 25, 2019 ......................
...............................................
...............................................
May 8, 2015 .................
November 8, 2016 ........
May 8, 2015 .................
November 8, 2016 ........
June 9, 2017 ................
May 8, 2015 .................
The patent rights in these inventions
have been assigned to the Government
of the United States of America.
The prospective exclusive patent
license territory may be worldwide and
a field of use limited to human
therapeutics for Hermansky-Pudlak
syndrome and idiopathic pulmonary
fibrosis.The invention covered by the
patents and patent applications
pertaining to HHS Ref. No. E–282–2012
relates to cannabinoid receptor 1 (CB1R)
inverse agonists. CB1R activation plays
a key role in appetitive behavior,
metabolism, and tissue fibrosis. Of
importance as a therapeutic target here
is that the receptor is expressed in both
peripheral tissue as well as the central
nervous system. The invention is a class
of pyrazole compounds that act as CB1
receptor inverse agonists and have been
shown effective at reducing obesity and
its associated metabolic consequences
while having no experimentally
discernable neuropsychotropic side
effects that are considered adverse,
unlike the earlier antagonists
rimonabant. These CB1R receptor
compounds were developed with the
goals of limiting their brain penetrance
without losing their metabolic efficacy
due to CB1 inverse agonism, and having
a primary metabolite directly targeting
enzymes involved in inflammatory and
fibrotic processes associated with
metabolic and other disorders. The
patents are both compositions of matter
and methods of use.
The inventions covered by HHS Ref.
E–140–2014–0 also pertain to pyrazole
CB1R receptor inverse agonists. In
addition, some of these compounds also
have a direct inhibitory effect on
inducible nitric oxide synthase (iNOS),
whereas another group of the
compounds directly activates AMP
kinase. There is evidence that the
metabolic effects of endocannabinoids
are mediated by CB1 receptors in
peripheral tissues. These dual-target
compounds may be useful for treating
metabolic disease and related
conditions such as obesity and diabetes
and their complications, including
various forms of tissue fibrosis, without
the dangerous side effects. This notice is
made in accordance with 35 U.S.C. 209
and 37 CFR part 404. The prospective
exclusive patent license will be royalty
VerDate Sep<11>2014
19:00 Nov 05, 2020
Jkt 253001
bearing and may be granted unless
within fifteen (15) days from the date of
this published notice, NHGRI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license.
Comments and objections submitted
to this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: November 2, 2020
Claire T. Driscoll,
Director, Technology Transfer Office,
National Human Genome Research Institute.
[FR Doc. 2020–24616 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
R13 Conferences and Scientific Meetings.
Date: December 11–14, 2020.
Time: 11:00 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Title
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20814 (Virtual Meeting).
Contact Person: Keith A Mintzer, Ph.D.,
Scientific Review Officer, Office of Review
Branch/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 207–G,
Bethesda, MD 20892–7924, (301) 827–7949,
mintzerk@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Institutional Training Grants.
Date: December 15, 2020.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–H,
Bethesda, MD 20892, (301) 827–7969,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24670 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\06NON1.SGM
06NON1
Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cognitive and Neuropathological
signatures of Alzheimer’s Disease, Brain
Injury and Aging.
Date: December 1, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Seetha Bhagavan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5194,
MSC 7846, Bethesda, MD 20892, (301) 237–
9838, bhagavas@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Mechanisms and Modulators of
Cognition, Impairment, Reward.
Date: December 1, 2020.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Andrea B. Kelly, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3182,
MSC 7770, Bethesda, MD 20892, (301) 455–
1761, kellya2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Pathophysiology of Eye Diseases:
Retinopathies, Degeneration and Infection.
Date: December 2, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alessandra C. Rovescalli,
Ph.D., Scientific Review Officer, National
Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Rm. 5205,
MSC 7846, Bethesda, MD 20892, (301) 435–
1021, rovescaa@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Language, Speech, Communication
and Motor Function.
Date: December 2, 2020.
Time: 11:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Katherine Colona Morasch,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
MSC 7848, Bethesda, MD 20892, (301) 594–
9147, moraschkc@csr.nih.gov.
VerDate Sep<11>2014
19:00 Nov 05, 2020
Jkt 253001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 2, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24672 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Long Acting Treatments for
HIV and HIV-Associated Co-Infections (R61/
R33 Clinical Trial Not Allowed).
Date: December 3, 2020.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Mohammed S. Aiyegbo,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy &
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70,
Rockville, MD 20852, (301) 761–7106,
mohammed.aiyegbo@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Frm 00035
Fmt 4703
Dated: November 2, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24666 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Amended
Notice of Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
71081
Sfmt 4703
Notice is hereby given of a change in
the meeting of the Special Emphasis
Panel, December 17, 2020, 10:00 a.m. to
5:30 p.m. This notice was published in
the Federal Register on October 26,
2020, 85 FR 207, Page 67747.
This notice is being amended to
change the date to December 22, 2020.
The meeting is closed to the public.
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24668 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Biology of
Development and Disease.
Date: November 20, 2020.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Child Health
and Human Development, 6710B Rockledge
E:\FR\FM\06NON1.SGM
06NON1
]]>Agencies
[Federal Register Volume 85, Number 216 (Friday, November 6, 2020)]
[Notices]
[Pages 71080-71081]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24672]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning
[[Page 71081]]
individuals associated with the grant applications, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cognitive and Neuropathological signatures
of Alzheimer's Disease, Brain Injury and Aging.
Date: December 1, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Seetha Bhagavan, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5194, MSC 7846, Bethesda, MD
20892, (301) 237-9838, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Mechanisms and Modulators of Cognition,
Impairment, Reward.
Date: December 1, 2020.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Andrea B. Kelly, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3182, MSC 7770, Bethesda, MD
20892, (301) 455-1761, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Pathophysiology of Eye Diseases:
Retinopathies, Degeneration and Infection.
Date: December 2, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alessandra C. Rovescalli, Ph.D., Scientific
Review Officer, National Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Rm. 5205, MSC 7846, Bethesda, MD
20892, (301) 435-1021, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Language, Speech, Communication and Motor
Function.
Date: December 2, 2020.
Time: 11:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Katherine Colona Morasch, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170, MSC 7848, Bethesda, MD
20892, (301) 594-9147, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 2, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-24672 Filed 11-5-20; 8:45 am]
BILLING CODE 4140-01-P
